X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Video: Barriers to results-based contracts

By Katie Koziara  |    April 17, 2018
Research suggests results-based contracts (RBCs)—also known as value-based contracts—have the potential to lower costs for patients and the health system. According to a recent analysis, these...   Read More

Improving care quality by engaging patients in shared decision making

By Randy Burkholder  |    March 22, 2018
With the rapid movement towards value-based payment and delivery in health care, it is critical not to leave one of the key players behind: the patient.     Read More

ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access

By Joe Vandigo  |    March 15, 2018
To address rising health care costs and help patients better access new medicines, biopharmaceutical companies are sharing financial risk with payers through new payment arrangements, like...   Read More

Clarity around anti-kickback statute needed to promote innovative payment arrangements

By Michelle Drozd  |    January 10, 2018
You may have recently read about how biopharmaceutical companies and insurers are working together to implement new approaches to paying for medicines, including through results-based contracts...   Read More

Video: What is a results-based contract?

By Katie Koziara  |    November 13, 2017
New medicines are revolutionizing how we fight disease, but too often patients have to fight to access innovative treatments. As part of the solution to this problem, biopharmaceutical companies...   Read More

Johnson & Johnson, Pfizer, Walgreens and other CEOs discuss value in the future of health care

By Holly Campbell  |    September 21, 2017
As part of The Value Collaborative, an initiative of America’s biopharmaceutical companies, we recently hosted an event with Bloomberg about unlocking and supporting value in the future of health...   Read More

PhRMA CEO in Forbes - How to negotiate better deals for prescription medicines

By Holly Campbell  |    June 2, 2017
    The following op-ed was authored by PhRMA president and CEO Stephen J. Ubl and published on Forbes here on June 2, 2017. The way our health care system currently pays for prescription...   Read More

ICYMI: Innovative payment models helping provide patient access to new medicines

By Holly Campbell  |    May 5, 2017
As we continue to make remarkable strides to treat our most costly and challenging diseases, there is a renewed focus on ensuring patients have access to the most innovative medicines....   Read More

RA medicines often demonstrate far greater benefits to patients than initially understood

By Lauren Neves  |    April 5, 2017
In the last decade, new therapies to treat rheumatoid arthritis (RA), a progressive and painful autoimmune disorder, have expanded patients’ treatment options and significantly improved outcomes,...   Read More

Stakeholders Agree: Modernize the legal framework to support move to value-driven health care

By Michelle Drozd  |    March 6, 2017
Modernizing certain laws and regulations to support the move to value-driven health care is an important step in moving our health care system forward. As part of PhRMA’s proactive policy...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates